Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

3,710.00p
   
  • Change Today:
    -40.00p
  • 52 Week High: 5,060.00
  • 52 Week Low: 3,225.00
  • Currency: UK Pounds
  • Shares Issued: 5.22m
  • Volume: 1,809
  • Market Cap: £193.65m

Bioventix Overview

Bioventix was founded in 2003 as a biotechnology company specialising in the creation and supply of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics. However, the antibody technology laboratory and some of the staff have been based at the same location in Farnham, Surrey, UK since the early 1990s.

Key Personnel

CEO: Peter John Harrison
CFO: Bruce Hiscock
Chairman: Ian James Nicholson
Independent Non-Executive Director: Joanne (Jo) Pisani
Independent Non-Executive Director: Nicholas (Nick) John McCooke
Non-Executive Dir:

Contact Details

Address: 27-28 Eastcastle Street, London, United Kingdom, W1W 8DH
Website: http://www.bioventix.com

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE AIM All-Share, FTSE AIM 100
ISIN: GB00B4QVDF07

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 3,710.00p
Change Today -40.00p
% Change -1.07 %
52 Week High 5,060.00
52 Week Low 3,225.00
Volume 1,809
Shares Issued 5.22m
Market Cap £193.65m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
67.17% below the market average67.17% below the market average67.17% below the market average67.17% below the market average67.17% below the market average
36.00% above the sector average36.00% above the sector average36.00% above the sector average36.00% above the sector average36.00% above the sector average
Price Trend
14.7% below the market average14.7% below the market average14.7% below the market average14.7% below the market average14.7% below the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
Income
2.30% above the market average2.30% above the market average2.30% above the market average2.30% above the market average2.30% above the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Growth
43.01% below the market average43.01% below the market average43.01% below the market average43.01% below the market average43.01% below the market average
17.65% below the sector average17.65% below the sector average17.65% below the sector average17.65% below the sector average17.65% below the sector average

Bioventix Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 07-Nov-24 11-Apr-24
Paid 21-Nov-24 26-Apr-24
Amount 87.00p 68.00p

Trades for 21-Nov-2024

Time Volume / Share Price
16:24 0 @ 3,700.00p
16:24 1 @ 3,700.00p
15:46 12 @ 3,794.00p
15:23 24 @ 3,746.00p
15:01 144 @ 3,794.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
CFO Bruce Hiscock

Top of Page